Category - Developments

Developments

Firefly’s FDA-cleared BNA platform underpins groundbreaking precision neuroscience study with Heidelberg University

Firefly Neuroscience (NASDAQ: AIFF) has announced its continued collaboration with Prof. Christian Schaaf, MD, Director of the Institute of Human Genetics at Heidelberg University Hospital and Chairman of Human Genetics...

July 14, 2025

Developments

Oncogene publishes remission for testicular cancer patient treated with MiNK’s iNKT cell therapy

MiNK Therapeutics (NASDAQ: INKT) has highlighted a publication in the peer-reviewed journal Oncogene describing a complete and durable remission in a patient with metastatic, treatment refractory testicular cancer...

July 11, 2025

Developments

China’s NMPA approves Ascentage’s lisaftoclax for CLL/SLL

Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855) has announced that China’s National Medical Products Administration (NMPA) has approved its proprietary novel Bcl-2 selective inhibitor lisaftoclax (APG-2575) for the...

July 10, 2025

Developments

PharmaJet enters MOU for needle-free vaccine delivery in Egypt

Closely held PharmaJet has announced the signing of a Memorandum of Understanding (MOU) with the Egyptian Unified Procurement Authority (UPA) and closely held EVA Pharma. The agreement aims to explore the integration of...

July 10, 2025

Developments

Cogent reports positive topline results from SUMMIT trial of bezuclastinib in NonAdvSM

Cogent Biosciences (NASDAQ: COGT) has announced positive topline results from the SUMMIT trial of bezuclastinib in patients with non-advanced systemic mastocytosis (NonAdvSM), achieving statistical significance across...

July 7, 2025

Developments

MedMira launches clinical trial for Multiplo TP/HIV self-test in Canada

MedMira (TSXV: MIR) has announced the launch of a clinical trial to evaluate its Multiplo TP/HIV rapid test for use as a self-test in Canada. Multiplo is a dual HIV and syphilis rapid self-test that delivers immediate...

July 7, 2025

Developments

Cyclacel highlights publication in Gut showing plogosertib is active in FLC

Cyclacel Pharmaceuticals (NASDAQ: CYCC; NASDAQ: CYCCP) has announced the publication of independent research in the peer-reviewed medical journal Gut demonstrating that plogosertib, a PLK1 inhibitor, is active in...

July 7, 2025

Developments

Cancer Cell highlights preclinical data of Tonix’s mTNX-1700 in gastric cancer models

Tonix Pharmaceuticals (NASDAQ: TNXP) has announced the publication of a paper in the peer-reviewed journal Cancer Cell, presenting data demonstrating that treatment with murine TNX-1700 (mTNX-1700) increased survival...

July 2, 2025

Developments

BriaCell adds two key clinical sites to Phase 3 study of lead candidate in MBC

BriaCell Therapeutics (NASDAQ: BCTX, BCTXW, BCTXZ; TSX: BCT) has announced the addition of two major cancer centers to its ongoing pivotal Phase 3 clinical study of Bria-IMT plus immune checkpoint inhibitor versus...

July 2, 2025

Developments

Clearmind doses first patient in trial of MEAI-based treatment for AUD

Clearmind Medicine (NASDAQ: CMND; FSE: CWY0) has announced that the first patient has been dosed in its Phase 1/2a clinical trial of its proprietary MEAI-based oral drug candidate, CMND-100, for the treatment of alcohol...

July 2, 2025

Category - Developments

Subscribe